PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.78%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-5.59%
Negative gross profit growth while Medical - Pharmaceuticals median is 2.53%. Seth Klarman would suspect poor product pricing or inefficient production.
-26.75%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-24.32%
Negative operating income growth while Medical - Pharmaceuticals median is 0.03%. Seth Klarman would check if structural or cyclical issues are at play.
-22.82%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-22.81%
Negative EPS growth while Medical - Pharmaceuticals median is 3.18%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-22.81%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 3.18%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.25%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
152.83%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 46.02%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
51.72%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 22.44%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
34.22%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 14.04%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
137.62%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 35.20% over a decade. Joel Greenblatt might see a standout compounder of earnings.
68.73%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 17.34%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
25.56%
3Y net income/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff would seek cost or revenue improvements to match peers.
310.55%
Equity/share CAGR of 310.55% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
81.59%
5Y equity/share CAGR of 81.59% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
35.06%
Positive short-term equity/share CAGR while Medical - Pharmaceuticals is negative. Peter Lynch finds a relative advantage vs. sector-level slowdown.
136.36%
Dividend/share CAGR of 136.36% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
160.00%
5Y dividend/share CAGR of 160.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
62.50%
3Y dividend/share CAGR of 62.50% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
3.80%
AR growth of 3.80% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
8.07%
Inventory growth of 8.07% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
0.32%
Asset growth of 0.32% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
2.65%
BV/share growth of 2.65% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-4.27%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-0.81%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.